This is still much too negative in my personal view.

New Post Public Reply Private Reply Replies (0) Message Board
Zolis_onkel FanMail #34448
737
This is still much too negative in my personal view.

AE37 development. It is very expensive to run a phase III clinical trial (phase II being successfully completed), and GNBT simply does not have the funding for. Hence the attempt to raise money through the NGIO IPO, which seems to be blocked for at least one year now by the SEC, who seems to keep investigating the company, starting with that deep dive in the 2019 10-K, and whatever else is currently going on.
Oral-Lyn development. Identical situation. It was very unfortunate that the FDA refused the first application for market approval. Then they did the reformulation in the lab, and now it requires another round of phase III clinical trials, which Joe repeatedly said (I personally asked such questions during more than one CC) that it is his intention to run the required clinical trials as soon as other parts of the company (e.g. Olaregen throuch Excellegen sales) have generated the required funding.
Excellegen sales. You actually are aware that we have been in a pandemic in the last 2 years. And again it was very unfortunate, and surely not Joe's or Olaregen's fault, that shortly after the received the VA hospital's holding company approval and sales numbers just started to ramp up, that all VA hospitals were shut down and thus Olaregen's business with them was shut down again.
General lack of communication from the companies to us shareholders. I think I made my standpoint very clear. It is obvious that the company is ready and willing to communicate with us. As a clear indication that this is so, I understand Todd's quick responses to a lot of emails with the message "we are currently not able to publish updates". So it has very little to do with not being willing to or intentionally wanting to leave us out in the cold and rain, but that they are - for some/whatever reason - currently NOT ABLE to do so. Someone/-thing is not allowing them to do so, or terrible consequences will apply.

I think you get my point, and I do not need to continue. It is very easy to criticize Joe's leadership and I am the last to glorify his achievements, however, I do not think that your blaming everything on him personally, is by no means fair neither.
Again, as mentioned before, I do not have more knowledge than anybody else on here, so especially the last part about communication or the lack thereof is, of course, only my assumption. But your "the sky is falling" message contain a lot of (negative) assumptions as well. So why not just give them the benefit of a doubt? And assume that the current situation is actually not their fault, and when I add 2 and 2 together, at least to me, this really sounds like it.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Network API Market by 2030

Updated Category News Views 125

Network API Market Overview As technology evolves, the demand for Network APIs is accelerating, and projections show the market will grow from USD 1.96 billion to an impressive USD 6.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 25.7% during the forecast period. This surge signifies a shift in how businesses leverage APIs to enhance connectivity...

Continue Reading
Quebec City Real Estate Market Sees Strong Activity Surge

Updated Category News Views 179

Quebec City Real Estate Market Activity in August As summer comes to a close, the residential real estate market in Quebec City is experiencing notable activity, achieving the second highest sales levels in 25 years for this month. This trend highlights the remarkable resilience and ongoing demand in a market that continues to change. Sales Data Overview In August, the...

Continue Reading
Understanding Market Trends: Income Strategies with IQQQ ETF

Updated Category News Views 151

Navigating the Current Tech Market Dynamics This year, the Nasdaq Composite index has outperformed other major indices, showing a solid increase of more than 21%. This surge in technology stocks has, however, been volatile, with the index recently experiencing a dip of roughly 2%. Concerns around a potential bubble in artificial intelligence have contributed to this...

Continue Reading
Boussard & Gavaudan Holding Limited: Latest NAV Update

Updated Category News Views 272

Boussard & Gavaudan Holding Limited Overview Boussard & Gavaudan Holding Limited is a well-known closed-ended investment company recognized within the finance industry for its effective management strategies. This article provides recent updates on the company's net asset value (NAV) and market activities. Estimated NAV Information The Directors of Boussard & Gavaudan...

Continue Reading
Currency Insights: Dollar and Yen Dynamics Amid Changes

Updated Category News Views 153

Current Trends in Currency Markets The US dollar is maintaining its strength as holiday trading continues with low volumes, while US Treasury yields are gradually rising. Although the dollar remains resilient against various currencies, it has shown some weakness against the Japanese yen and Canadian dollar lately. Markets are keenly observing the impact of potential...

Continue Reading